Humacyte announces publication of Symvess results in real-world combat

Humacyte (HUMA) announced the publication in Oxford Academic’s Military Medicine of positive long-term results from its humanitarian program using Symvess to treat wartime vascular trauma injuries in Ukraine. The publication, titled “Evaluating the Safety and Efficacy of Humacyte Acellular Tissue-Engineered Vessel in a Real-World Combat Setting: A Retrospective Observational Multicenter Study,” reported that trauma patients with wartime injuries treated with Symvess were observed to have a continued high rate of patency, 100% limb salvage, and zero cases of conduit infection in 17 patients with extremity injuries followed for up to 18 months. Battlefield vascular injuries are some of the most difficult for surgeons to treat because of time pressure and the potential for infection. Unlike traditional autologous vein grafts, which require harvesting a patient’s vein during surgery, Symvess is designed to be immediately available off-the-shelf – saving critical surgical time in wartime situations. Symvess has also showed low rates of infection. The publication described the outcomes of 17 patients treated with treated with Symvess whose injuries included combat-related extremity vascular trauma from gunshots, blasts, and shrapnel. At 30 days of follow up, the primary measurement point in the study, patients treated with Symvess had incurred zero deaths, zero amputations, and zero cases of infection. The 30-day primary and secondary patency rate was 93.8%. The long-term results published for the first time in Military Medicine confirmed these earlier positive outcomes. At up to 18 months of follow up, patients were observed to have suffered zero deaths, zero infections, and zero amputations. Furthermore, Symvess demonstrated continued high levels of patency and no instances of immunological rejection.